Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BMN 110 in Morquio A Syndrome
NCT01609062Phase 2Terminated
- Sponsor
- BioMarin Pharmaceutical
- Start
- Apr 2012
- Primary completion
- Nov 2014
- Modality
- Replacement Enzymes
- Countries
- 4
01
Overview
A Phase 2 trial of elosulfase alfa in mucopolysaccharidosis type IVA, sponsored by BioMarin Pharmaceutical. Started Apr 2012; status: terminated.
02
Drugs
elosulfase alfa
03
Conditions
mucopolysaccharidosis type IVA
Beyond the preview
Go deeper on NCT01609062.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01609062.